title: A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases.
abstract: We describe a novel and general way of generating high affinity peptide (HAP) binders to receptor tyrosine kinases (RTKs), using a multi-step process comprising phage-display selection, identification of peptide pairs suitable for hetero-dimerization (non-competitive and synergistic) and chemical synthesis of heterodimers. Using this strategy, we generated HAPs with K(D)s below 1 nM for VEGF receptor-2 (VEGFR-2) and c-Met. VEGFR-2 HAPs bound significantly better (6- to 500-fold) than either of the individual peptides that were used for heterodimer synthesis. Most significantly, HAPs were much better (150- to 800-fold) competitors than monomers of the natural ligand (VEGF) in various competitive binding and functional assays. In addition, we also found the binding of HAPs to be less sensitive to serum than their component peptides. We believe that this method may be applied to any protein for generating high affinity peptide (HAP) binders.
authors.affiliation: Ernst Felder Laboratories, Bracco Research USA, Princeton, NJ 08540, USA. ajay.shrivastava@bru.bracco.com
authors.forename: A
authors.initials: A
authors.lastname: Shrivastava
authors.forename: M A
authors.initials: MA
authors.lastname: von Wronski
authors.forename: A K
authors.initials: AK
authors.lastname: Sato
authors.forename: D T
authors.initials: DT
authors.lastname: Dransfield
authors.forename: D
authors.initials: D
authors.lastname: Sexton
authors.forename: N
authors.initials: N
authors.lastname: Bogdan
authors.forename: R
authors.initials: R
authors.lastname: Pillai
authors.forename: P
authors.initials: P
authors.lastname: Nanjappan
authors.forename: B
authors.initials: B
authors.lastname: Song
authors.forename: E
authors.initials: E
authors.lastname: Marinelli
authors.forename: D
authors.initials: D
authors.lastname: DeOliveira
authors.forename: C
authors.initials: C
authors.lastname: Luneau
authors.forename: M
authors.initials: M
authors.lastname: Devlin
authors.forename: A
authors.initials: A
authors.lastname: Muruganandam
authors.forename: A
authors.initials: A
authors.lastname: Abujoub
authors.forename: G
authors.initials: G
authors.lastname: Connelly
authors.forename: Q L
authors.initials: QL
authors.lastname: Wu
authors.forename: G
authors.initials: G
authors.lastname: Conley
authors.forename: Q
authors.initials: Q
authors.lastname: Chang
authors.forename: M F
authors.initials: MF
authors.lastname: Tweedle
authors.forename: R C
authors.initials: RC
authors.lastname: Ladner
authors.forename: R E
authors.initials: RE
authors.lastname: Swenson
authors.forename: A D
authors.initials: AD
authors.lastname: Nunn
mesh_terms: D019281:Dimerization; D016503:Drug Delivery Systems; D015195:Drug Design; D004357:Drug Synergism; D006801:Humans; D019151:Peptide Library; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D025941:Protein Interaction Mapping; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism
chemical_list: D019151:Peptide Library; D010455:Peptides; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases; D040301:Vascular Endothelial Growth Factor Receptor-2